Advertisement

Chance der Lebensverlängerung und Minderung der Lebensqualität durch intensive Chemotherapie

  • W. Schreml
Conference paper
Part of the Verhandlungen der Deutschen Gesellschaft für Innere Medizin book series (VDGINNERE, volume 92)

Zusammenfassung

Die Therapieentscheidungen bei potentiell kurativen, aber belastenden und risikoreichen Behandlungsstrategien fallen in die Polarität der Partner Patient und Arzt. Während der Arzt auf der Basis naturwissenschaftlich „abgesicherter“ Erkenntnisse eine Therapieplanung vorschlägt, muß der Patient die Chancen und Risiken tragen — mit welchem Grad der Einsicht auch immer er die Entscheidung fällt oder geschehen läßt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aisner J, Whitacre M, Van Echo DA, Wiernik PH (1982) Combination chemotherapy for small cell cancer of the lung. Cancer Treat Rep 66:221–230PubMedGoogle Scholar
  2. Bunn PA, Ihde DC (1981) Small cell bronchogenic carcinoma: A review of therapeutic results. In: Livingston RB (ed) Lung Cancer. M. Nijhoff, Den Haag, pp 169–208Google Scholar
  3. Cohen MH, Creaven PJ, Fossieck BE et al. (1977) Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 61:349–354PubMedGoogle Scholar
  4. Edmonson JH, Lagakos SW, Selawry OS et al. (1976) Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung. Cancer Treat Rep 60:925–932PubMedGoogle Scholar
  5. Ettinger DS, Mehta CR, Abeloff JC et al. (1986) A randomized comparison of conventional chemotherapy with immediate alternation of non-cross resistant chemotherapy in extensive disease (ED) small cell lung cancer (SCLC). ASCO Meeting Abstracts Vol. 5, No. 666Google Scholar
  6. Evans WK, Murray N, Feld R et al. (1986) Canadian multicenter randomized trial comparing standard (SD) and alternating (A) combination chemotherapy in extensive small cell lung cancer (SCLC). ASCO Meeting Abstracts Vol. 5, No. 662Google Scholar
  7. Frei E, Canellos GP (1980) Dose: a critical factor in cancer chemotherapy. Am J Med 69:585–594PubMedCrossRefGoogle Scholar
  8. Ginsberg SJ, Comis RL, Gottlieb AJ et al. (1979) Long-term survivorship in small-cell anaplastic lung carcinoma. Cancer Treat Rep 63:1347–1349PubMedGoogle Scholar
  9. Goldie JH, Coldman AJ, Gudauskas GA (1982) Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66:439–449PubMedGoogle Scholar
  10. Goodman GE, Blasko J for the SWOG (1986) Concurrent chemotherapy with VP-16/Vincristine/Adriamycin/Cyclophosphamide (EVAC) versus alternating chemotherapy with VP-16/cis-Platinum/ and Vincristine/Adriamycin/Cyclophosphamide (VPP/VAC) in limited small cell lung cancer: a Southwest Oncology Group Study (SWOG). ASCO Meeting Abstracts Vol. 5, No. 663Google Scholar
  11. Greco FA, Perez C, Einhorn LH et al. (1986) Combination chemotherapy with or without concurrent thoracic radiotherapy (RT) in limited-stage (LD) small cell lung cancer (SCLC): a phase III trial of the Southeastern Cancer StudyGoogle Scholar
  12. Group (SEG). ASCO Meeting Abstracts Vol. 5 No. 698Google Scholar
  13. Hansen M, Hansen HH, Dombernowsky PL (1980) Long-term survival in small cell carcinoma of the lung. JAMA 244:247–250PubMedCrossRefGoogle Scholar
  14. Holoye PY, Libnoch JA, Anderson T et al. (1985) Combined Methotrexate and highdose Vincristine chemotherapy with radiation therapy for small cell bronchogenic carcinoma. Cancer 55:1436–1445PubMedCrossRefGoogle Scholar
  15. Ihde DC (1984) Current status of chemotherapy for small cell carcinoma of the lung. Cancer 54:2722–2728PubMedCrossRefGoogle Scholar
  16. Johnson BE, Ihde DC, Bunn PA et al. (1985) Patients with small cell lung cancer treated with combination chemotherapy with or without irradiation. Ann Int Med 103:430–438PubMedCrossRefGoogle Scholar
  17. Johnson DH, De Leo MJ, Hande KR et al. (1986) High-dose (HD) Cyclophosphamide (C), Eteposide (E), and cis-Platin (P) induction therapy in extensive-stage (ED) small cell lung cancer (SCLC). ASCO Meeting Abstracts Vol. 5, No. 697Google Scholar
  18. Klastersky J, Nicaise C, Longeval E et al. (1982) Cisplatin, Adriamycin, and Eteposide (CAV) for remission induction of small-cell bronchogenic carcinoma. Cancer 50:652–658PubMedCrossRefGoogle Scholar
  19. Klastersky J, Sculier JP, Dumont JP etal. (1985) Combination chemotherapy with Adriamycin, Eteposide, and Cylophosphamide for small cell carcinoma of the lung. Cancer 56:71–75PubMedCrossRefGoogle Scholar
  20. Lee JS, Umsawasdi T, Carr DT et al. (1986) Timing of elective brain irradiation (EBI) in small cell lung cancer (SCLC): a critical factor for brain metastasis-free survival. ASCO Meeting Abstracts Vol. 5, No. 731Google Scholar
  21. Lowenbraun S, Bartolucci A, Smalley RV et al. (1979) The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma. Cancer 44:406–413PubMedCrossRefGoogle Scholar
  22. Lowenbraun S, Birch R, Buchanan R etal. (1984) Combination chemotherapy in small cell lung carcinoma. Cancer 54:2344–2350PubMedCrossRefGoogle Scholar
  23. Luikart SD, Propert K, Zimmer B etal. (1986) High dose Eteposide (VP-16) in ambulatory patients with extensive small cell cancer of the lung (SCCL). ASCO Meeting Abstracts Vol. 5, No. 705Google Scholar
  24. Mandelbaum I, Williams SD, Hornback NB etal. (1978) Combined therapy for small cell undifferentiated cancer of the lung. J Thorac Cardiovasc Surg 76:292–296PubMedGoogle Scholar
  25. Marschke R, Jett J, Everson L et al. (1986) Randomized trial of CAV with or without VP-16 for limited disease small cell lung cancer (SCC). ASCO Meeting Abstracts Vol. 5, No. 669Google Scholar
  26. McNeil BJ, Weichselbaum R, Pauker SG (1978) Fallacy of the five-year survival in lung cancer. N Engl J Med 299:1397–1401PubMedCrossRefGoogle Scholar
  27. Morstyn G, Ihde DC, Lichter AS et al. (1984) Small cell lung cancer 1973–1983: early progress and recent obstacles. Int J Radiat Oncol Biol Phys 10:515–534PubMedCrossRefGoogle Scholar
  28. Norton L, Simon R (1977) Size, sensitivity to therapy and design of treatment schedules. Cancer Treat Rep 61:1307–1317PubMedGoogle Scholar
  29. Pedinielli F, Beaulieu R, Latreille J et al. (1986) Vincristine (V), Cyclophosphamide (C) Adriamycin (A) with or without Eteposide (E) in small cell lung cancer (SCLC) ASCO Meeting Abstracts Vol. 5, No. 670Google Scholar
  30. Perry MC, Eaton WL, Chahinian P et al. (1986) Chemotherapy (CT) with or without radiation therapy (RT) in limited small cell cancer of the lung (SCCL). ASCO Meeting Abstracts Vol.5, No. 678Google Scholar
  31. Smith IE, Evans BD, Harland SJ et al. (1985) High-dose Cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treat ment of small cell lung carcinoma. Cancer Chemother Pharmacol 14:120–124PubMedCrossRefGoogle Scholar
  32. Vogl SE, Mehta C (1982) High dose Cyclophosphamide in the induction chemotherapy of small cell lung cancer: minor improvements in the rate of remission and in survival. Abstracts of 3rd World Conference on Lung Cancer, Tokyo, No. 168Google Scholar
  33. Volk SA, Mansour RF, Gandara DR et al. (1984) Morbidity of long-term survivors of small cell carcinoma of the lung. Cancer 54:25–27PubMedCrossRefGoogle Scholar

Copyright information

© J. F. Bergmann Verlag, München 1986

Authors and Affiliations

  • W. Schreml
    • 1
  1. 1.Abteilung Innere Medizin Kreiskrankenhaus GünzburgDeutschland

Personalised recommendations